ARTICLE | Emerging Company Profile
Medicenna: Cytokines with a punch
Medicenna developing toxin-fused cytokines as alternative to ADCs
February 17, 2014 8:00 AM UTC
Medicenna Therapeutics Inc.'s Empowered Cytokines provide an alternative to antibody-drug conjugates that are relatively cheap to produce and create a more homogenous product.
The company's compounds are fusion proteins of a cytokine and a bacterial or human toxin. Like ADCs, Empowered Cytokines require overexpression of a target receptor on the tumor cell surface that is internalized after binding, bringing the toxin into the cell...